ASH 2014 | Phase III ASPIRE study of carfilzomib, lenalidomide and dexamethasone in relapsed myeloma

Jeffery Matous

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jeffery Matous (Colorado Blood Cancer Institute, Denver, CO) discusses the randomised, open-label, multicentre phase III ASPIRE study of carfilzomib, lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma.

Share this video  
Similar topics